|
14 Feb |
Amgen v. Sanofi – How Wands Factors make Biotech Claims “Magically” Disappear |
|
4 Feb |
Interesting Developments at the EPO |
|
18 Jan |
Illumina v. Ariosa – Ariosa Petitions for Cert. |
|
13 Jan |
American Axle & Manufacturing v. Neapco Holdings–Part II |
|
11 Jan |
American Axle Petitions for Cert. |
|
30 Nov |
Vectura v. GlaxoSmithKline – How to Keep Process Limitations out of Composition Claims |
|
13 Nov |
C. R. Bard v. Angiodynamics – It’s a Labelled Injection Port, not a Label |
|
9 Nov |
Immunex v. Sanofi-Aventis – The “Mystery Dance” of Claim Construction |
|
12 Oct |
Biogen v. EMD Serono – “A Nest of Limitations” |
|
18 Sep |
USPTO Announces Program to Eliminate Filing Fees in Exchange for Early Publication of COVID-19 Applications |
